Biologics, or biopharmaceuticals, are protein therapeutics drugs that are produced using recombinant DNA technology. Over the past two decades, Biologics have revolutionized the treatment landscape in several therapeutic areas, especially in Oncology & Autoimmune disorders. The biggest advantage of Biologics over conventional medicines is that they are targeted and highly specific. However, Biologics are more complex and difficult to develop and are therefore relatively expensive. As a consequence, in developing countries they are unaffordable for most people.
We view generic biopharmaceuticals as an integral part of our mid to long term growth strategy and believe that building depth in development and manufacturing capabilities will be critical in accessing this opportunity. We have made significant efforts in this direction and have over the years succeeded in creating world class infrastructure and a highly capable team.
Strengths
- Proven generic biopharmaceutical development capabilities with two marketed products - GrafeelTM (filgrastim) and RedituxTM (rituximab), in emerging markets
- Developed and launched Reditux (rituximab) - the world's first generic monoclonal antibody
- The product portfolio spans multiple therapeutic areas - oncology, auto-immune diseases and CNS
- cGMP facilities to manufacture Biologics, in adherence with global regulatory requirements at a significant cost advantage
Pipeline
We have a pipeline of 8 generic biopharmaceuticals in various stages of development with two in clinical development stage.
